<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2021-20-3-8-18</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1283</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Особенности серопревалентности к SARS-CoV-2 населения Среднего и Южного Урала в начальный период пандемии COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Peculiarities of Seroprovalence to SARS-CoV-2 in the Population of the Middle and Southern Urals in the Early Period of the COVID-19 Pandemic</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анна Юрьевна Попова – д. м. н., профессор, руководитель.</p><p>Москва</p></bio><bio xml:lang="en"><p>Anna Yu. Popova  – Dr. Sci. (Med.), professor, leader </p><p>Moscow</p></bio><email xlink:type="simple">depart@gsen.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8701-280X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ежлова</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ezhlova</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Борисовна Ежлова  – к. м. н., заместитель руководителя. </p><p>Москва</p></bio><bio xml:lang="en"><p>Elena B. Yehlova – Cand. Sci. (Med.), Deputy Head </p><p>Moscow</p></bio><email xlink:type="simple">ezhlova_eb@rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5651-1331</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мельникова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Melnikova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Альбина Андреевна Мельникова  – к. м. н., заместитель начальника Управления эпидемиологического надзора. </p><p>Москва</p></bio><bio xml:lang="en"><p>Albina A. Melnikova – Cand. Sci. (Med.), Deputy Head of the Department of Epidemiological Surveillance </p><p>Moscow</p></bio><email xlink:type="simple">melnikova_aa@gsen.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2723-1496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнов</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnov</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вячеслав Сергеевич Смирнов – д. м. н., профессор, ведущий научный сотрудник лаборатории молекулярной иммунологии. </p><p>197101, Санкт-Петербург, ул. Мира, д. 14.</p></bio><bio xml:lang="en"><p>Vyacheslav S. Smirnov  – Dr. Sci. (Med.), professor, Leading Researcher </p><p>14, st. Mira, St. Petersburg, 197101</p></bio><email xlink:type="simple">vssmi@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9921-3505</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лялина</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyalina</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Владимировна Лялина – д. м. н., профессор, заведующая лабораторией эпидемиологии инфекционных и неинфекционных заболеваний. </p><p>197101, Санкт-Петербург, ул. Мира, д. 14.</p></bio><bio xml:lang="en"><p>Lyudmila V. Lyalina – Dr. Sci. (Med.), professor, Head of the Laboratory of Epidemiology of  Infectious and Non-infectious Diseases</p><p>14, st. Mira, St. Petersburg, 197101</p></bio><email xlink:type="simple">lyalina@pasteurorg.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0360-7695</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козловских</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlovskikh</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дмитрий Николаевич Козловских – руководитель. </p><p> г. Екатеринбург</p></bio><bio xml:lang="en"><p>Dmitry N. Kozlovskikh – Head of  the Department</p><p>Yekaterinburg</p></bio><email xlink:type="simple">Kozlovskih_DN@66rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5705-8850</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лучинина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Luchinina</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Васильевна Лучинина  – д. м. н., заместитель руководителя. </p><p> г. Челябинск</p></bio><bio xml:lang="en"><p>Svetlana V. Luchinina  – Dr. Sci. (Med.), Deputy Head of  the Department </p><p>Chelyabinsk</p></bio><email xlink:type="simple">spn@chel.surnet.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7357-9496</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Викторович Романов  – главный врач. </p><p>г. Свердловск</p></bio><bio xml:lang="en"><p>Sergey V. Romanov  – Chief Physician </p><p>Sverdlovsk</p></bio><email xlink:type="simple">Romanov_SV@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0677-4571</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валеуллина</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Valeullina</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Николаевна Валеуллина  – главный врач. </p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Natalya N. Valeullina  – Chief Physician</p><p>Chelyabinsk</p></bio><email xlink:type="simple">ValeullinaNN@chel.surnet.ru</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2249-4748</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Диконская</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dikonskaya</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Викторовна Диконская – заместитель руководителя. </p><p>г. Екатеринбург</p></bio><bio xml:lang="en"><p>Olga V. Dikonskaya – Deputy Head of the Department </p><p>Yekaterinburg</p></bio><email xlink:type="simple">Dikonskaya_OV@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7220-0456</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чиркова</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chirkova</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Григорьевна Чиркова – заведующая вирусологической лабораторией. </p><p>г. Челябинск</p></bio><bio xml:lang="en"><p>Galina G. Chirkova – Head of Virological Laboratory</p><p>Chelyabinsk</p></bio><email xlink:type="simple">viruslab@chel.surnet.ru</email><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8394-627X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малых</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Malykh</surname><given-names>O. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Леонидовна Малых  – начальник отдела социально-гигиенического мониторинга и  планирования деятельности Управления организации контрольно-надзорной деятельности и  оказания государственных услуг Федеральной службы по надзору в сфере защиты прав потребителей и  благополучия человека. </p><p>г. Екатеринбург</p></bio><bio xml:lang="en"><p>Olga L. Malykh – Head of the Department of Social and Hygienic Monitoring and Planning of Activities of the Office for Organization of Control and Supervision Activities and Provision of  Public Services of  the Federal Service for Supervision of  Consumer Rights Protection and Human Welfare </p><p>Yekaterinburg</p></bio><email xlink:type="simple">Malyh_ol@rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5236-3458</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пономарева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponomareva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анжелика Владимировна Пономарева  – заместитель руководителя. </p><p>г. Екатеринбург</p></bio><bio xml:lang="en"><p>Anzhelika V. Ponomareva – Deputy Head of the Department </p><p>Yekaterinburg</p></bio><email xlink:type="simple">Ponomareva_AV@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3247-9269</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чистякова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chistyakova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Викторовна Чистякова  – заместитель главного врача. </p><p>г. Свердловск</p></bio><bio xml:lang="en"><p>Irina V. Chistyakova – Deputy Chief Physician </p><p>Sverdlovsk</p></bio><email xlink:type="simple">Chistyakova_IV@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1751-3462</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Килячина</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kilyachina</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анастасия Сергеевна Килячина – заведующая лабораторией контроля биологических факторов, врач-вирусолог. </p><p>г. Свердловск</p></bio><bio xml:lang="en"><p>Anastasia S. Kilyachina  – Head of  the laboratory for the  control of  biological factors, doctor-virologist </p><p>Sverdlovsk</p></bio><email xlink:type="simple">Kilyachina_AS@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4117-7174</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юровских</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yurovskikh</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Иванович Юровских  – заместитель главного врача. </p><p>г. Свердловск</p></bio><bio xml:lang="en"><p>Andrey I. Yurovskikh  – Deputy Chief Physician </p><p>Sverdlovsk</p></bio><email xlink:type="simple">Yurovskikh_AI@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5298-3526</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алина Алексеевна Котова  – врач-эпидемиолог отдела социально-гигиенического мониторинга. </p><p>г. Свердловск</p></bio><bio xml:lang="en"><p>Alina A. Kotova – doctor-epidemiologist of the department of social and hygienic monitoring </p><p>Sverdlovsk</p></bio><email xlink:type="simple">Kotova_AA@66.rospotrebnadzor.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4571-8799</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тотолян</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Totolian</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арег Артемович Тотолян  – академик РАН, д. м. н., профессор, директор. </p><p>197101, Санкт-Петербург, ул. Мира, д. 14.</p></bio><bio xml:lang="en"><p>Areg A. Totolian – Academician of the Russian Academy of Sciences, Dr. Sci. (Med.), professor, Director</p><p>14, st. Mira, St. Petersburg, 197101</p></bio><email xlink:type="simple">pasteur@pasteurorg.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФБУН «Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера» Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg Pasteur Institute St. Petersburg</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Управление Роспотребнадзора по Свердловской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rospotrebnadzor Administration in the Sverdlovsk Region</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Управление Роспотребнадзора по Челябинской обл.</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rospotrebnadzor Administration in the Chelyabinsk Region</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФБУЗ «Центр гигиены и эпидемиологии в Свердловской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Center for Hygiene and Epidemiology in the Sverdlovsk Region</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФБУЗ «Центр гигиены и эпидемиологии в Челябинской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Center for Hygiene and Epidemiology in the Chelyabinsk Region</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2021</year></pub-date><volume>20</volume><issue>3</issue><fpage>8</fpage><lpage>18</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Смирнов В.С., Лялина Л.В., Козловских Д.Н., Лучинина С.В., Романов С.В., Валеуллина Н.Н., Диконская О.В., Чиркова Г.Г., Малых О.Л., Пономарева А.В., Чистякова И.В., Килячина А.С., Юровских А.И., Котова А.А., Тотолян А.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Смирнов В.С., Лялина Л.В., Козловских Д.Н., Лучинина С.В., Романов С.В., Валеуллина Н.Н., Диконская О.В., Чиркова Г.Г., Малых О.Л., Пономарева А.В., Чистякова И.В., Килячина А.С., Юровских А.И., Котова А.А., Тотолян А.А.</copyright-holder><copyright-holder xml:lang="en">Popova A.Y., Ezhlova E.B., Melnikova A.A., Smirnov V.S., Lyalina L.V., Kozlovskikh D.N., Luchinina S.V., Romanov S.V., Valeullina N.N., Dikonskaya O.V., Chirkova G.G., Malykh O.L., Ponomareva A.V., Chistyakova I.V., Kilyachina A.S., Yurovskikh A.I., Kotova A.A., Totolian A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1283">https://www.epidemvac.ru/jour/article/view/1283</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. В конце 2019 г. мир столкнулся с новым коронавирусом (SARS-CoV-2), В январе 2020 г. ВОЗ объявила эпидемию, связанную с SARS-CoV-2, чрезвычайной ситуацией в области здравоохранения международного значения и в марте охарактеризовала принявшее мировой масштаб распространение болезни как пандемию.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Провести сравнительный анализ серопревалентности населения Свердловской и Челябинской областей – крупнейших административнотерриториальных образований Среднего и Южного Урала – на фоне пандемии COVID-19.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Работа проводилась по программе первого этапа оценки серопревалентности населения РФ по единой методике, разработанной Роспотребнадзором РФ при участии НИИ эпидемиологии и микробиологии им. Пастера. Отбор участников проводили методом анкетирования и рандомизации. Наличие антител к нуклеокапсиду SARS-CoV-2 определяли в сыворотке крови иммуноферментным методом</p></sec><sec><title>Результаты</title><p>Результаты. При сравнительном анализе результатов было показано, что уровень заболеваемости COVID-19 в Челябинской области был стабильно ниже, а серопревалентность на первом этапе исследования статистически достоверно выше (p&lt;0/05), чем в Свердловской области. Было установлено, что заболеваемость в обеих областях имела прямую корреляционную зависимость от плотности населения (r = 0,59; p &lt; 0,05). Не выявлено различий между сравниваемыми областями в показателях серопревалентности среди реконвалесцентов, лиц, имевших контакты с больными COVID-19, и бессимптомных волонтеров с положительным ПЦР-тестом. При анализе серопревалентных волонтеров в обеих областях было показано, что число лиц с бессимптомным течением варьировало в пределах 94,4 ± 1,2% – 95,0 ± 0,95%. Эти данные свидетельствуют о том, что большинство волонтеров переносило COVID-19 бессимптомно.</p></sec><sec><title>Выводы</title><p>Выводы. Сравнительное исследование показало статистически значимое преобладание серопревалентности среди населения Челябинской области. Установлено, что повышение серопревалентности на популяционном уровне сопровождалось снижением заболеваемости. Показана прямая зависимость между плотностью населения и уровнем заболеваемости. Более 90% серопозитивных лиц сравниваемых областей демонстрировали бессимптомное течение коронавирусной инфекции.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. At the end of 2019, the world was confronted with a novel coronavirus (SARS-CoV-2), In January 2020, WHO declared an epidemic related to SARS-CoV-2, a health emergency of international importance, and in March characterized the spread of the world. diseases like a pandemic.</p></sec><sec><title>Purpose of the study</title><p>Purpose of the study. Conduct a comparative analysis of the seroprevalence of the population of the Sverdlovsk and Chelyabinsk regions – the largest administrative territorial entities of the Middle and Southern Urals – against the backdrop of the COVID-19 pandemic.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The work was carried out under the program of the first stage of assessing the seroprevalence of the population of the Russian Federation according to a unified methodology developed by Rospotrebnadzor of the Russian Federation with the participation of the Saint Petersburg Pasteur Institute. The selection of participants was carried out by the method of questioning and randomization. The presence of antibodies to the SARS-CoV-2 nucleocapsid was determined in blood serum by the enzyme immunoassay.</p></sec><sec><title>Results</title><p>Results. Comparative analysis of the results showed that the incidence rate of COVID-19 in the Chelyabinsk region was consistently lower, and the seroprevalence at the first stage of the study was statistically significantly higher (p &lt;0/05) than in the Sverdlovsk region. It was found that the incidence in both regions had a direct correlation with population density (r = 0.59; p &lt;0.05). There were no differences between the compared areas in terms of seroprevalence among convalescents, people who had contact with COVID-19 patients, and asymptomatic volunteers with a positive PCR test. When analyzing seroprevalent volunteers in both regions, it was shown that the number of asymptomatic individuals varied within 94.4 ± 1.2% – 95.0 ± 0.95%. These data indicate that the majority of volunteers tolerated COVID-19 asymptomatically.</p></sec><sec><title>Conclusions</title><p>Conclusions. A comparative study showed a statistically significant predominance of seroprevalence among the population of the Chelyabinsk region. It was found that an increase in seroprevalence at the population level was accompanied by a decrease in morbidity. Shown is a direct relationship between population density and the incidence rate. More than 90% of seropositive individuals in the compared areas showed asymptomatic course of coronavirus infection.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>серопревалентность</kwd><kwd>бессимптомное течение</kwd><kwd>Свердловская область</kwd><kwd>Челябинская область</kwd><kwd>население</kwd><kwd>плотность населения</kwd><kwd>заболеваемость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>seroprevalence</kwd><kwd>asymptomatic course</kwd><kwd>Sverdlovsk region</kwd><kwd>Chelyabinsk region</kwd><kwd>population</kwd><kwd>population density</kwd><kwd>morbidity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Novel Coronavirus(2019-nCoV) Situation Report – 11. Доступно на: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_2.</mixed-citation><mixed-citation xml:lang="en">Novel Coronavirus(2019-nCoV) Situation Report  – 11. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_2.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Доступно на: https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</mixed-citation><mixed-citation xml:lang="en">WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Morens, D.M., Fauci, A.S. Emerging Pandemic Diseases: How We Got To COVID-19. Cell. 2020. Vol. 183. N3. P. 837. doi: 10.1016j.cell.2020.10.022.</mixed-citation><mixed-citation xml:lang="en">Morens, D.M., Fauci, A.S., Emerging Pandemic Diseases: How We Got To COVID-19. Cell. 2020; 183(3):837. doi: 10.1016/j.cell.2020.10.022.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Xu X., Chen, P., Wang, J., et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. China Life Sci. 2020. № 63. P. 457–460. doi. 10.1007/s11427-020-1637-5.</mixed-citation><mixed-citation xml:lang="en">Xu X., Chen, P., Wang, J., et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. China Life Sci. 2020; 63:457–460. doi. 10.1007/s11427-020-1637-5.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bchetnia M., Girard C., Duchaine C., Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J. Inf. Public Health. 2020. Vol. 13., N 11. P. 1601–1610. doi: 10.1016/j.jiph.2020.07.011.</mixed-citation><mixed-citation xml:lang="en">Bchetnia M., Girard C., Duchaine C., Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Inf. Public Health. 2020; 13(11):1601–1610. doi: 10.1016/j.jiph.2020.07.011.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Clemente-Suárez V.J., Hormeño-Holgado A., Jiménez M., et al. Dynamics of population immunity due to the herd effect in the COVID-19 pandemic. Vaccines (Basel). 2020. Vol. 8, N 2. С. E236. doi: 10.3390/vaccines8020236.</mixed-citation><mixed-citation xml:lang="en">Clemente-Suárez V.J., Hormeño-Holgado A., Jiménez M., et al.Dynamics of population immunity due to the herd effect in the COVID-19 pandemic. Vaccines (Basel). 2020; 8(2):E236. doi: 10.3390/vaccines8020236.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Liu L., Wei Q., Lin Q., et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 201. Vol. 4, N 4. P. e123158. doi: 10.1172/jci.insight.123158.</mixed-citation><mixed-citation xml:lang="en">Liu L., Wei Q., Lin Q., et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 201; 4(4):e123158. doi: 10.1172/jci.insight.123158.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">El-Sayed A., Aleya L., Kamel M. COVID-19: a new emerging respiratory disease from the neurological perspective Environ Sci Pollut Res Int. 2021. P. 1–15. doi: 10.1007/s11356-021-12969-9.</mixed-citation><mixed-citation xml:lang="en">El-Sayed A., Aleya L., Kamel M. COVID-19: a new emerging respiratory disease from the neurological perspective Environ Sci Pollut Res Int. 2021; 15: 1–15. doi: 10.1007/s11356-021-12969-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ortiz-Prado E., Simbaña-Rivera K., Gómez- Barreno L., et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020. Vol. 98, N 1. P. 115094. doi: 10.1016j.diagmicrobio.2020.115094.</mixed-citation><mixed-citation xml:lang="en">Ortiz-Prado E., Simbaña-Rivera K., Gómez- Barreno L., et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020; 98(1):115094. doi: 10.1016/j.diagmicrobio.2020.115094.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А.Ю., Ежлова Е.Б., Мельникова А.А. и др. Распределение серопревалентности к SARS-CоV-2 среди жителей Тюменской области в эпидемическом периоде COVID-19. Журнал микробиологии, эпидемиологии и иммунобиологии. 2020. Т. 97, № 5. С. 392–400. doi: 10.36233/0372-9311-2020-97-5-1.</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Distribution of SARS-CоV-2  seroprevalence among residents of the Tyumen Region during the COVID-19  epidemic period. Journal of microbiology, epidemiology and immunobiology = Zhurnal mikrobiologii, èpidemiologii I immunobiologii. 2020; 97(5): 392–400. (In Russian) doi: doi: 10.36233/0372-9311-2020-97-5-1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А.Ю., Ежлова Е.Б., Мельникова А.А. и др. Популяционный иммунитет к SARS-CoV-2 среди населения Санкт-Петербурга в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020. № 3. С.124–130. doi: 10.21055/0370-1069-2020-3-124-130.</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., et al. Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; 3:124–130. (In Russian). doi: 10.21055/0370-1069-2020-3-124-130.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А.Ю., Ежлова Е.Б., Мельникова А.А. и др. Оценкa популяционого иммунитета к SARS-CoV-2 среди населения Ленинградской области в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020. № 3. С. 114–123. doi: 10.21055/0370-1069-2020-3-114-123.</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Mel’nikova A.A., Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2020; 3:114–123. (In Russian). doi: 10.21055/0370-1069-2020-3-114-123.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine, 1998, vol. 17. Р. 857–887. doi: 10.1002/(sici)1097-0258(19980430)17:8&lt;857::aid-sim777&gt;3.0.co;2-e.</mixed-citation><mixed-citation xml:lang="en">Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine, 1998, vol. 17, pp. 857–887. doi: 10.1002/(sici)1097-0258(19980430)17:8&lt;857::aid-sim777&gt;3.0.co;2-e.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А.Ю., Андреева Е.Е., Бабура Е.А. и др. Особенности формирования cеропревалентности населения Российской Федерации к нуклеокапсиду SARS-CoV-2 в первую волну эпидемии COVID-19. Инфекция и иммунитет. 2021. Т. 11, № 2. С. 297–323. doi:10.15789/2220-7619-FOD-1684.</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Andreeva E.E., Babura E.A., et al. Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the firstwave of the COVID-19 epidemic in the Russian Federation. Russian Journal of Infection and Immunity=Infektsya i immunitet. 2021; 11(2):297–323. doi:10.15789/2220-7619-FOD-1684.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rocklöv J, Sjödin H High population densities catalyze the spread of COVID-19.J Travel Med. 2020; 27, N 3. P. taaa038. doi: 10.1016/j.jinf.2020.06.067.</mixed-citation><mixed-citation xml:lang="en">Rocklöv J, Sjödin H High population densities catalyze the spread of COVID-19.J Travel Med. 2020: taaa038. doi: 10.1093/jtm/taaa038.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sanche S., Lin Y.T., Xu C., et al High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020. Vol.26, N7. P. 1470–1477. doi: 10.3201/eid2607.200282.</mixed-citation><mixed-citation xml:lang="en">Sanche S., Lin Y.T., Xu C., et al. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470–1477. doi: 10.3201/eid2607.200282.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh K.A., Jordan K., Clyne B., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020. Vol.81, N3. P.357–371. doi: 10.1016/j.jinf.2020.06.067.</mixed-citation><mixed-citation xml:lang="en">Walsh K.A., Jordan K., Clyne B., et al. SARS-CoV-2  detection, viral load and infectivity over the course of an infection. J Infect. 2020; 81(3):357–371. doi: 10.1016/j.jinf.2020.06.067.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mason R.J. Pathogenesis of COVID-19 from a cell biologic perspective Eur Respir J. 2020. Vol.55, N4. P. 2000607. doi: 10.1183/13993003.00607-2020.</mixed-citation><mixed-citation xml:lang="en">Mason R.J. Pathogenesis of COVID-19 from a cell biologic perspective Eur Respir J. 2020; 55(4):2000607. doi: 10.1183/13993003.00607-2020.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R., Dana T., Jungbauer R., et al. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings: A Living Rapid Review. Ann Intern Med. 2020. Vol.173, N7. P. 542–555. doi: 10.7326/M20-3213</mixed-citation><mixed-citation xml:lang="en">Chou R., Dana T., Jungbauer R., et al. Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings: A Living Rapid Review. Ann Intern Med. 2020; 173(7):542–555. doi: 10.7326/M20-3213</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Liang M., Gao L., et al. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am J Infect Control. 2020. (in press) doi: 1016/j.ajic.2020.12.007.</mixed-citation><mixed-citation xml:lang="en">Li Y., Liang M., Gao L., et al. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. Am J Infect Control. 2020; (in press). doi: 1016/j.ajic.2020.12.007.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 Euro Surveill. 2020; Vol.25, N10. P. 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.</mixed-citation><mixed-citation xml:lang="en">Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 Euro Surveill. 2020; 25(10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao D., Wang M., Wang M., et al Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. Int J Infect Dis. 2020. N 99. P. 219–225. doi: 10.1016/j.ijid.2020.07.082.</mixed-citation><mixed-citation xml:lang="en">Zhao D., Wang M., Wang M., et al. Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. Int J Infect Dis. 2020; 99:219–225. doi: 10.1016/j.ijid.2020.07.082.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Loos C., Atyeo C., Fischinger S., et al. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. mSphere. 2020. Vol. 5, N5. P. e00622-20. doi: 10.1128/mSphere.00622-20.</mixed-citation><mixed-citation xml:lang="en">Loos C., Atyeo C., Fischinger S., et al. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. mSphere. 2020; 5(5): e00622-20. doi: 10.1128/mSphere.00622-20.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Buitrago-Garcia D., Egli-Gany D., Counotte M.J., et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020. Vol.17, N9.P. e1003346. doi: 10.1371/journal.pmed.1003346.</mixed-citation><mixed-citation xml:lang="en">Buitrago-Garcia D., Egli-Gany D., Counotte M.J., et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020; 17(9):e1003346. doi: 10.1371/journal.pmed.1003346.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Oran D.P., Topol E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020. Vol. 173, N5. P. 362–367. doi: 10.7326/M20-3012.</mixed-citation><mixed-citation xml:lang="en">Oran D.P., Topol E.J. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review. Ann Intern Med. 2020; 173(5):362–367. doi: 10.7326/M20-3012.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S., Meyler P., Mozel M., et al. Asymptomatic carriage and transmission of SARS-CoV-2: What do we know? Can J Anaesth. 2020. Vol.: 67, N10. P.1424–1430. doi: 10.1007/s12630-020-01729-x.</mixed-citation><mixed-citation xml:lang="en">Lee S., Meyler P., Mozel M., Tauh T., Merchant R.Asymptomatic carriage and transmission of SARS-CoV-2: What do we know? Can J Anaesth. 2020; 67(10):1424–1430. doi: 10.1007/s12630-020-01729-x.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Yu X. Modeling return of the epidemic: Impact of population structure, asymptomatic infection, case importation and personal contacts/ Travel Med Infect Dis. 2020. N37. P. 101858. doi: 10.1016/j.tmaid.2020.101858.</mixed-citation><mixed-citation xml:lang="en">Yu X. Modeling return of the epidemic: Impact of population structure, asymptomatic infection, case importation and personal contacts/ Travel Med Infect Dis. 2020; 37:101858. doi: 10.1016/j.tmaid.2020.101858.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Randolph H. E., Barreiro L. B. Herd Immunity: Understanding COVID-19 Immunity. 2020. Vol.52, N5. P. 737–741. doi: 10.1016j.immuni.2020.04.012.</mixed-citation><mixed-citation xml:lang="en">Randolph H. E., Barreiro L. B. Herd Immunity: Understanding COVID-19 Immunity. 2020, 52(5): 737–741. doi: 10.1016/j.immuni.2020.04.012.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
